» Articles » PMID: 11689783

De Novo Malignancies After Liver Transplantation: a Major Cause of Late Death

Overview
Journal Liver Transpl
Date 2001 Nov 2
PMID 11689783
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

1. Recurrent and de novo malignancies are the second leading causes of late death in liver transplant recipients, following age-related cardiovascular complications. 2. The increased incidence of de novo malignancies in liver transplant recipients compared with the general population reflects their demographic makeup, known preexistent risk factors for cancer, greater rate of chronic viral infection, and actions of exogenous immunosuppression. 3. The greatest incidence of de novo malignancies is seen in cancers associated with chronic viral infections, such as Epstein-Barr virus-associated posttransplant lymphoproliferative disease, and skin cancers, including squamous cell carcinoma and Kaposi's sarcoma. 4. Although a greater incidence of such malignancies as oropharyngeal malignancy and colorectal cancer was noted, there did not appear to be an increased risk for liver transplant recipients matched for age, sex, and length of follow-up using modified life-table technique and Surveillance Epidemiology End Result data with a similar at-risk group. However, they may present with more advanced stages of disease. 5. An increased incidence of de novo cancers in chronically immunocompromised liver transplant recipients demands careful long-term screening protocols to help facilitate diagnosis at an earlier stage of disease.

Citing Articles

Clinical outcomes of gastric cancer surgery after liver transplantation.

Kim S, Lee H, Alzahrani F, Kim J, Kim S, Kim S Ann Surg Treat Res. 2023; 104(2):101-108.

PMID: 36816738 PMC: 9929436. DOI: 10.4174/astr.2023.104.2.101.


Successful pancreatoduodenectomy of duodenal malignancy after orthotopic liver transplantation: A case report.

Ji L, Xu D, Zhu C, Xu J, Cao H, Zhao G Front Surg. 2023; 9:1068215.

PMID: 36684304 PMC: 9852733. DOI: 10.3389/fsurg.2022.1068215.


Annual Meeting of the Canadian Association for the Study of the Liver (CASL), the Canadian Network on Hepatitis C (CANHEPC) and the Canadian Association of Hepatology Nurses (CAHN) 2021 Abstracts.

Can Liver J. 2022; 4(2):113-248.

PMID: 35991765 PMC: 9204943. DOI: 10.3138/canlivj.4.2.abst.


The Spectrum of Malignant Neoplasms among Liver Transplant Recipients: Sociodemographic Factors, Mortality, and Hospital Burden.

Haider M, Bapatla A, Ismail R, Chaudhary A, Iqbal S, Haider S Int J Med Sci. 2022; 19(2):299-309.

PMID: 35165515 PMC: 8795812. DOI: 10.7150/ijms.66533.


Pancreatic adenocarcinoma in liver transplant recipients: a case series.

Rauf M, Ziogas I, Sealock J, Davis L, Izzy M, Alexopoulos S Ann Pancreat Cancer. 2021; 4.

PMID: 34825179 PMC: 8612297. DOI: 10.21037/apc-21-4.